Key terms

About PLRX

Pliant Therapeutics, Inc. engages in the discovery and development of therapies for fibrotic diseases. It offers product discovery engine. The company is pursuing drug development programs for a range of fibrotic diseases, focusing on tissue-specific integrin modulation and TGF-ß1 signaling inhibition. The company was founded by Bradley Backes, Bill De Grado, Hal Chapman, and Dean Sheppard in June 2015 and is headquartered in South San Francisco, CA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest PLRX news

Mar 13 7:11am ET Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Bioventus (BVS) and Pliant Therapeutics (PLRX) Mar 12 12:50pm ET Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO) and Pliant Therapeutics (PLRX) Mar 12 7:48am ET Pliant Therapeutics announces accelerated bexotegrast development plan Mar 08 7:56am ET Pliant Therapeutics: Strong Buy Rating on Promising Pipeline and Solid Financials Mar 01 1:00am ET Maintaining Buy Rating on Pliant Therapeutics: Promising Clinical Advances and Solid Financial Footing Feb 29 6:40am ET Buy Rating Affirmed for Pliant Therapeutics Amid Promising Drug Pipeline and Financial Stability Feb 28 7:47am ET Oppenheimer Keeps Their Buy Rating on Pliant Therapeutics (PLRX) Feb 28 7:40am ET Pliant Therapeutics price target lowered to $50 from $53 at RBC Capital Feb 28 7:31am ET Piper Sandler Sticks to Their Buy Rating for Pliant Therapeutics (PLRX) Feb 28 7:16am ET Pliant Therapeutics (PLRX) Gets a Buy from RBC Capital Feb 28 6:50am ET Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT), Pliant Therapeutics (PLRX) and Viridian Therapeutics (VRDN) Feb 28 6:38am ET Buy Rating Affirmed for Pliant Therapeutics Amidst Promising Clinical Trial Progress Feb 28 6:26am ET Buy Rating Affirmed for Pliant Therapeutics on Promising Pipeline and Strong Financials Feb 28 2:09am ET 3 Best Stocks to Buy Now, 2/28/2024, According to Top Analysts Feb 27 10:20pm ET Analysts’ Top Healthcare Picks: PROCEPT BioRobotics (PRCT), Pliant Therapeutics (PLRX) Feb 27 9:27pm ET Pliant Therapeutics (PLRX) Receives a Buy from TD Cowen Feb 27 4:24pm ET Pliant Therapeutics reports Q4 EPS (69c), consensus (81c) Feb 08 7:19am ET Pliant Therapeutics price target lowered to $43 from $48 at Canaccord Feb 07 8:31am ET Buy Rating on Pliant Therapeutics: Positive Outlook on Bexotegrast Despite Investor Concerns Feb 06 7:29am ET Pliant Therapeutics price target lowered to $47 from $49 at Oppenheimer Feb 06 5:39am ET Buy Rating on Pliant Therapeutics: Promising IPF Drug Outlook Overcomes PSC Concerns Feb 06 4:16am ET Pliant Therapeutics Achieves Success in Liver Disease Trial Feb 06 4:08am ET 3 Best Stocks to Buy Now, 2/6/2024, According to Top Analysts Feb 05 1:45pm ET Pliant Therapeutics: Overcoming PSC Trial Hurdles with Promising IPF Prospects Feb 05 8:35am ET Piper Sandler Reaffirms Their Buy Rating on Pliant Therapeutics (PLRX) Feb 05 8:15am ET Pliant Therapeutics (PLRX) Receives a Buy from Stifel Nicolaus Feb 05 6:20am ET Analysts Offer Insights on Healthcare Companies: Pliant Therapeutics (PLRX), Siemens Healthineers AG (OtherSEMHF) and 4D Molecular Therapeutics (FDMT) Feb 05 6:14am ET Pliant Therapeutics price target lowered to $48 from $52 at H.C. Wainwright Feb 04 4:42pm ET Pliant Therapeutics announces data from INTEGRIS-PSC Phase 2a trial Jan 07 5:39am ET BTIG Reaffirms Their Buy Rating on Pliant Therapeutics (PLRX) Jan 02 12:13pm ET The biotech stocks to own in 2024, according to Piper Sandler

No recent news articles are available for PLRX

No recent press releases are available for PLRX

PLRX Financials

1-year income & revenue

Key terms

PLRX Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

PLRX Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms